These results confirmed that suppression of CPT1A by siRNA or etomoxir could both block the utilization of fatty acids and the production of ATP, which might result in the regulation of apoptosis and proliferation and eventually reverse oxaliplatin resistance in colon cancer. This evidence concerns the gene CPT1A and malignant colon neoplasm.